ClinicalTrials.gg
CompletedNCT07549581Updated Apr 24, 2026

A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode

A Phase 1 interventional study of SEP-380135 and Placebo in Schizophrenia, Major Depressive Disorder (MDD) and Bipolar Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry.
  • Registered 1 year 5 months after the study started (first participant enrolled Nov 2024, registered Apr 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd. — 3 open to participants now, 4 under way, 3 of them phase 3. Schizophrenia · Otsuka Holdings Co., Ltd..

Enrollment
86th of 111
43 · median 125
Started
2024
the only one that year
Phase 1
34 of 120
1 open now
Registered
120th of 120
by date

Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 86th largest by enrollment of the 111 interventional ones that give a count, is the only one that started in 2024, is one of 34 in phase 1, and was the 120th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

3 of the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple dose oral administration of SEP-380135 in participants with schizophrenia or with a major depressive episode associated with bipolar I or II disorder or major depressive disorder (MDD).

03

Conditions studied

  • Schizophrenia
  • Major Depressive Disorder (MDD)
  • Bipolar Disorder
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • from 18.0 to 35.0 kilograms per square meter (kg/m\^2) (inclusive).
  • Participants with a primary diagnosis of schizophrenia (cohorts 1 to 3) or bipolar I or II disorder or MDD (cohort 4) for at least 1 year (at screening), as established by clinical review, using the as a reference, and confirmed using the Mini international neuropsychiatric interview (MINI).
  • For cohorts 1 to 3: deemed to have residual symptoms of schizophrenia at screening (i.e., be at least "mildly ill" per CGI-S criteria [CGI-S greater than or equal to (≥) 3]) and a PANSS criteria of less than or equal to (≤) 75. For cohort 4 only: deemed to be currently experiencing an MDE. Participants must be at least "moderately ill" per CGI-S criteria (CGI-S ≥ 4).
  • Ability to provide written, prior to initiation of any trial-related procedures, and ability, in the opinion of the PI, to comply with all the requirements of the trial.

Exclusion criteria

Exclusion Criteria:

  • Attempted suicide within 12 months prior to screening
  • A disorder or history of a condition, or previous gastrointestinal conditions that may interfere with drug absorption, distribution, metabolism, excretion, gastrointestinal motility, or pH, or a history of abnormality of the hepatic (including participants with moderate [ Class B] and severe [Child-Pugh Class C] hepatic impairment) or renal system (a less than (\<) 60 milliliters per minute (mL/min)), or a history of malabsorption, bowel resection, bariatric surgery or gastric band/lap band surgery, or is on medications that might interfere with gastric motility.
  • (AST), alanine aminotransferase (ALT), or ≥ 2 times the upper limit of the reference ranges provided by the safety laboratory at screening, or total bilirubin ≥ 2 times the upper limit of reference (except for participants with Gilbert's syndrome or similar condition).
  • Has any clinically significant unstable medical condition, clinically significant chronic disease, or any psychiatric symptom or diagnosis that in the opinion of the investigator, MM, or sponsor would pose a risk to the participant or the scientific objectives of the trial.

Note: Other protocol-specified Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants receive SEP-380135 Dose Level 1, orally once daily (QD) from Day 1 to Day 14.

    Drug: SEP-380135

  • Experimental
    Cohort 2

    Participants receive SEP-380135 Dose Level 2 orally once daily (QD) from Day 1 through Day 14.

    Drug: SEP-380135

  • Experimental
    Cohort 3

    Participants receive SEP-380135 Dose Level 3 orally once daily (QD) from Day 1 through Day 14.

    Drug: SEP-380135

  • Experimental
    Cohort 4

    Participants receive SEP-380135 Dose Level 4 orally once daily (QD) from Day 1 through Day 14.

    Drug: SEP-380135

  • Placebo comparator
    Placebo

    Participants receive SEP-380135 matching-placebo orally orally once daily (QD) from Day 1 to Day 14.

    Drug: Placebo

Interventions

  • DrugSEP-380135

    oral capsule.

  • DrugPlacebo

    Placebo capsule.

06

What researchers measure

Primary outcomes

  1. All Cohorts: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Treatment Emergent Adverse Events (TEAEs) Leading to Trial Discontinuation

    Time frame: Up to Day 44

  2. All Cohorts: Percentage of Participants With Suicidal Ideation or Suicidal Behavior Using the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to Day 18

  3. All Cohorts: Percentage of Participants With Withdrawal Symptoms Using the 20-Item Physician Withdrawal Checklist (PWC-20)

    Time frame: Up to Day 44

  4. All Cohorts: Percentage of Participants With Change From Baseline in Potentially Clinically Relevant Laboratory Tests

    Time frame: Baseline, Day 18

  5. All Cohorts: Percentage of Participants With Change From Baseline in Potentially Clinically Relevant Vital Signs

    Time frame: Baseline, Day 18

  6. All Cohorts: Percentage of Participants With Change From Baseline in Potentially Clinically Relevant Orthostatic Effects

    Time frame: Baseline, Day 18

  7. All Cohorts: Actual Values of Weight

    Time frame: Up to Day 18

  8. All Cohorts: Change From Baseline in Weight

    Time frame: Baseline, Day 18

  9. All Cohorts: Actual Values of Body Mass Index (BMI)

    Time frame: Up to Day 18

  10. All Cohorts: Change From Baseline in BMI

    Time frame: Baseline, Day 18

  11. All Cohorts: Actual Values of Waist Circumference

    Time frame: Up to Day 18

  12. All Cohorts: Change From Baseline in Waist Circumference

    Time frame: Baseline, Day 18

  13. All Cohorts: Percentage of Participants With Change From Baseline in 12-Lead Electrocardiogram (ECG)

    Time frame: Baseline, Day 18

  14. All Cohorts: Actual Values of QT interval corrected using Fridericia's Formula (QTcF)

    Time frame: Up to Day 18

  15. All Cohorts: Change From Baseline in QTcF

    Time frame: Baseline, Day 18

  16. Cohorts 1, 2, and 3: Actual Values of Clinician-Administered Dissociative States Scale (CADSS) Score

    Time frame: Up to Day 18

  17. Cohorts 1, 2, and 3: Change From Baseline in CADSS Score

    Time frame: Baseline, Day 18

  18. All Cohorts: Actual Values of Drug Effect Questionnaire (DEQ) Scored Using Visual Analog Scale Score

    Time frame: Up to Day 18

  19. All Cohorts: Change From Baseline in DEQ Scored Using Visual Analog Scale Score

    Time frame: Baseline, Day 18

  20. Cohorts 1, 2, and 3: Actual Values of Barnes Akathisia Rating Scale (BARS) Score

    Time frame: Up to Day 18

  21. Cohorts 1, 2, and 3: Change From Baseline in BARS Score

    Time frame: Baseline, Day 18

  22. Cohorts 1, 2, and 3: Actual Values of Abnormal Involuntary Movement Scale (AIMS) Score

    Time frame: Up to Day 18

  23. Cohorts 1, 2, and 3: Change From Baseline in AIMS Score

    Time frame: Baseline, Day 18

  24. Cohorts 1, 2, and 3: Actual Values of Simpson Angus Scale (SAS) Score

    Time frame: Up to Day 18

  25. Cohorts 1, 2, and 3: Change From Baseline in SAS Score

    Time frame: Baseline, Day 18

  26. Cohorts 1, 2, and 3: Actual Values of Positive and Negative Syndrome Scale (PANSS) Score

    Time frame: Up to Day 18

  27. Cohorts 1, 2, and 3: Change From Baseline in PANSS Score

    Time frame: Baseline, Day 18

  28. All Cohorts: Actual Values of Clinical Global Impressions-Severity Scale (CGI-S) Score

    Time frame: Up to Day 18

  29. All Cohorts: Change From Baseline in CGI-S Score

    Time frame: Baseline, Day 18

  30. Cohorts 1, 2, and 3: Actual Values of Calgary Depression Scale for Schizophrenia (CDSS) Score

    Time frame: Up to Day 18

  31. Cohorts 1, 2, and 3: Change From Baseline in CDSS Score

    Time frame: Baseline, Day 18

  32. All Cohorts: Percentage of Participants With Change From Baseline in Physical Examinations

    Time frame: Baseline, Day 18

  33. All Cohorts: Percentage of Participants With Change From Baseline in Neurological Examinations

    Time frame: Baseline, Day 18

  34. Cohort 4: Actual Values of Hamilton Anxiety Rating Scale (HAM-A) Score

    Time frame: Up to Day 18

  35. Cohort 4: Change From Baseline in HAM-A Score

    Time frame: Baseline, Day 18

  36. Cohort 4: Actual Values of Montgomery-Asberg Depression Rating Scale (MADRS) Score

    Time frame: Up to Day 18

  37. Cohort 4: Change From Baseline in MADRS Score

    Time frame: Baseline, Day 18

  38. Cohort 4: Actual Values of Young Mania Rating Scale (YMRS) Score

    Time frame: Up to Day 18

  39. Cohort 4: Change From Baseline in YMRS Score

    Time frame: Baseline, Day 18

  40. All Cohorts: Percentage of Participants With Changes in Quantitative Sleep Parameters Measured Using Electroencephalography (EEG)

    Time frame: Up to Day 17

  41. All Cohorts: Apparent Clearance (CL/F) of SEP-380135

    Time frame: Day 14

  42. All Cohorts: Volume of Distribution (Vz/F) of SEP-380135

    Time frame: Day 14

  43. All Cohorts: Maximum Plasma Concentration (Cmax) of SEP-380135

    Time frame: Day 14

  44. All Cohorts: Area Under the Drug Concentration-time Curve From Time Zero Predose to 24 hours Postdose (AUC0-24h) of SEP-380135

    Time frame: Day 14

Secondary outcomes

  1. All Cohorts: Cmax of SEP-380135 and its Metabolites

    Time frame: Days 1 and 14

  2. All Cohorts: Time to Maximum Plasma Concentration (tmax) of SEP-380135 and its Metabolites

    Time frame: Days 1 and 14

  3. All Cohorts: AUC0-24h of SEP-380135 and its Metabolites

    Time frame: Days 1 and 14

  4. All Cohorts: Observed Plasma Concentration at 24 hours Postdose (C24h) of SEP-380135

    Time frame: Days 1 and 14

  5. All Cohorts: Terminal Phase Elimination Half-Life (t1/2,z) of SEP-380135 and its Metabolites

    Time frame: Day 14

  6. All Cohorts: Serum Concentration of SEP-380135 at Steady-State

    Time frame: Day 14

07

Study locations

1 site
  • Collaborative Neuroscience Research, LLC
    Los Alamitos, California 90720, United States
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Sep 2025, 10 months.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 10 months is above that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2026
First posted
Apr 24, 2026
StartActual
Nov 7, 2024
Primary completionActual
Sep 12, 2025
CompletionActual
Sep 12, 2025
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07549581
Responsible party
Sponsor
First posted
Apr 24, 2026
Start date
Nov 7, 2024
Primary completion
Sep 12, 2025
Completion
Sep 12, 2025
Last update
Apr 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion